Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
Latest Stock Exchange announcements
Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer
Lokelma approved in the US for the treatment of adults with hyperkalaemia
Regulatory submission in Japan for Forxiga in type-1 diabetes
Results of Annual General Meeting held on 18 May 2018
Q1 2018 Results
Our Annual Report provides a wide range of information about our global business.
Answers to frequently asked shareholder questions.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development